TADLIQ
Peaktadalafil
NDAORALSUSPENSION
Approved
Jun 2022
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
20
Mechanism of Action
Phosphodiesterase 5 Inhibitors
Pharmacologic Class:
Phosphodiesterase 5 Inhibitor
Clinical Trials (5)
Actual Use Trial of Tadalafil 5 mg
Started Jan 2025
2,250 enrolled
Erectile Dysfunction
A Study of Macitentan/Tadalafil Combination Administered a Fixed-dose Combination Formulation Compared to the Reference Free Combination of Macitentan and Tadalafil
Started Apr 2021
18 enrolled
Healthy
A Study of Macitentan and Tadalafil as a Fixed Dose Combination and the Free Combination in Healthy Adult Participants
Started Jan 2020
62 enrolled
Healthy
Marrow Infiltrating Lymphocytes - Non-Small Cell Lung Cancer (MILs™ - NSCLC) Alone or in Combination With Nivolumab With or Without Tadalafil in Locally Advanced and Unresectable or Metastatic NSCLC
Started Oct 2019
19 enrolled
Non Small Cell Lung CancerLung CancerLung Cancer Metastatic+5 more
Efficacy and Safety of Combination Ambrisentan and Tadalafil in Patients With Portopulmonary Hypertension
Started Oct 2017
0Portopulmonary HypertensionPulmonary HypertensionCirrhosis, Liver
Loss of Exclusivity
LOE Date
Dec 24, 2038
155 months away
Patent Expiry
Dec 24, 2038